Semaglutide, a diabetes and weight-loss drug, reduced brain inflammation and accelerated cellular recovery in mice, according to research published in Nature Communications [psypost.org]. Researchers are studying whether drugs that mimic the hormone GLP-1 could help explain clinical observations linking their use to lower dementia rates, but the experiment tested a mouse model, not people [psypost.org]. The study examined how a metabolic drug affects brain health during inflammation. Separate mouse research discussed by ScienceDaily examined whether restoring the brain protein Menin could reverse age-related changes [psypost.org] [sciencedaily.com]. Highlights: • Immune genetics: The report notes that genetics research points to immune pathways as major drivers of cognitive decline over time [psypost.org]. • Metabolic risk: Obesity and type 2 diabetes independently increase the risk of developing dementia, providing part of the rationale for examining GLP-1 receptor agonists in brain health [psypost.org]. Perspectives: Semaglutide researchers examined the drug’s effects across multiple brain cell types rather than treating inflammation as a single-cell process [psypost.org]. (PsyPost) ScienceDaily reported that the Menin study identified a brain pathway that may influence aging throughout the body, linking brain changes to effects beyond cognition [sciencedaily.com]. (ScienceDaily) Sources: • The diabetes and weight-loss drug semaglutide was found to calm brain inflammation and accelerate cellular recovery in mice, suggesting it could potentially protect against cognitive decline and neurodegenerative conditions like Alzheimer's disease - reddit.com • Weight-loss drug semaglutide accelerates recovery from brain inflammation in mice - psypost.org • Scientists restore a brain protein and reverse signs of aging in mice - sciencedaily.com --- 📰 Story aggregated by Kagi News